Side effect guides
What’s common, what’s serious and what to track for each GLP-1 medication.
- GLP-1 Side EffectsThe most common GLP-1 side effects for semaglutide and tirzepatide, when they tend to appear, which warning signs need a doctor, and how tracking helps.
- Ozempic Side EffectsWhat the Ozempic label says about side effects in type 2 diabetes — stomach symptoms by dose, low blood sugar with insulin or sulfonylureas, eyes, and when to call.
- Wegovy Side EffectsWegovy side effects at the 2.4 mg maintenance dose — stomach symptoms, fatigue, hair loss, skin sensations, gallbladder and heart rate — from the FDA label.
- Mounjaro Side EffectsMounjaro side effects for people with type 2 diabetes — how common nausea and diarrhea were in trials, low blood sugar with insulin, eye checks and when to get help.
- Zepbound Side EffectsZepbound side effects from the weight-management and sleep apnea trials — how often nausea, hair loss and fatigue came up, what eases with time and when to get help.
- Semaglutide Side EffectsSemaglutide side effects across Ozempic, Wegovy, Rybelsus and compounded vials — what's shared, what differs between pill and shot, and FDA's dosing-error warning.
- Tirzepatide Side EffectsTirzepatide side effects across Mounjaro and Zepbound, how they compared with semaglutide head to head, and what the FDA says about compounded versions.
- Oral Wegovy Side EffectsSide effects of the daily Wegovy pill (oral semaglutide 25 mg) from the FDA label and OASIS 4 trial — stomach symptoms, skin sensations and when to get help.
- Foundayo Side EffectsFoundayo (orforglipron) side effects from the FDA label — how often nausea, constipation and vomiting came up, what eases with time, and when to call your doctor.
- Orforglipron Side EffectsOrforglipron side effects from its 72-week trials — how rates rose with dose, what differed with type 2 diabetes, lab changes and drug interactions.
- Retatrutide Side EffectsRetatrutide is investigational. What its TRIUMPH trials reported so far on nausea, skin sensations, blood pressure and stopping treatment, for trial participants.
